Trials / Unknown
UnknownNCT04946500
Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- University Hospital, Brest · Academic / Other
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Accepted
Summary
The alternatives to the combination of Fluoroquinolone and Rifampicin in prosthetic joint infections (PJI) caused by staphylococcus are currently unclear. Clindamycin is prescribed as dual therapy in this indication, and provides many advantages. We conducted a multicenter retrospective observational study evaluating the efficacy and safety of Clindamycin in prosthetic joint infections due to staphylococcus between January 2013 and December 2019.
Conditions
Timeline
- Start date
- 2021-05-15
- Primary completion
- 2021-07-15
- Completion
- 2021-10-15
- First posted
- 2021-07-01
- Last updated
- 2021-07-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04946500. Inclusion in this directory is not an endorsement.